Impact of Smoking and Nicotine on the Risk of Being Infected With COVID-19

Completed

• Conditions: Smoking Behaviors
• Interventions: Diagnostic Test: Serological test for COVID-19.

• Registration Number: NCT04429815
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Several studies have shown that smokers have a higher risk of developing a severe form of COVID-19 once a person has been infected. This is explained by the damage caused by smoking at the bronchopulmonary level and an overexpression of some coronavirus receptors at the pulmonary level when exposed to tobacco. In contrast, recent data indicate that smokers are proportionally less infected with the COVID-19 virus since all available cohort data from around the world show a very low rate of smokers among COVID-19 infected subjects. The mechanisms at the origin of this protective effect are not known. All of these data lead us to question the real role of nicotine in the protective effect of tobacco observed in the general population against infection by the COVID-19 virus.

The objectives are :

* To show that subjects taking nicotine substitutes as part of a smoking cessation program are less infected with COVID-19 than non-smokers.

* To show that active smokers are less infected with COVID-19 than non-smokers.

* To compare the percentage of positive serological tests in subjects taking nicotine substitutes to the percentage of positive serological tests in active smokers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-06-11
• Study First Submitted QC: 2020-06-11
• Study First Posted: 2020-06-12
• Study Start: 2020-08-25
• Primary Completion: 2021-05-26
• Study Completion: 2021-05-26
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-16
• Last Update Posted: 2021-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

• Age > 18 years old
• Subject who will require a serological test for COVID-19 virus as part of standard of care.
• Group 1: Active smoker since October 2019
• Group 2: Smoker undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019
• Group 3: Non-smoker

Exclusion Criteria

• Inpatient subject
• Subjects with a chronic serious pathology modifying the risk of exposure to COVID-19

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Non-smoking.	Serological test for COVID-19.	Person who's never smoked before.
Active smokers.	Serological test for COVID-19.	Active smokers since October 2019.
Smokers undergoing smoking cessation	Serological test for COVID-19.	Smokers undergoing smoking cessation and taking nicotine substitutes on a regular basis since October 2019.

Primary Outcome Measures

Name	Time	Method
Percentage of patients with a positive serological test for COVID-19.	1 day	Percentage of patients with a positive serological test for COVID-19.

Trial Locations

Locations (1)

CHRU Nancy; 🇫🇷 Vandoeuvre-les-Nancy, France